Conmed (CNMD) Tops Q3 EPS by 4c

Conmed (NASDAQ: CNMD) reported Q3 EPS of $0.80, $0.04 better than the analyst estimate of $0.76. Revenue for the quarter came in at $248.8 million versus the consensus estimate of $255.53 million.

GUIDANCE:

Conmed sees FY2021 EPS of $3.18-$3.23, versus the consensus of $3.19.

For earnings history and earnings-related data on Conmed (CNMD) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Amneal gets FDA approval for lanreotide injection, launches immediately
• UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'